自然启发的黄金 (I) 作为抗癌剂的复合物:连接物设计,结构-活动关系和机制
Amrin Begum1,2, Navya Pn1, Pooran Kumar1
1Centre for Advanced Materials and Industrial Chemistry, School of Science, STEM College, RMIT University, Melbourne 3000, Australia.
Cancers
|February 27, 2026
概括
灵感来自大自然的黄金 (I) 复合物显示出强大的抗癌活性. 连接体设计和金色协调是提高细胞毒性,稳定性和理解它们的机制以促进未来药物开发的关键.
科学领域:
- 药用化学 医学化学
- 无机化学 无机化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自然灵感的配体,包括自然产品和生物灵感的图案,是新型黄金的有价值来源.
- 金 ((I) 复合物越来越多地被研究其临床前抗癌疗效.
- 了解结构活动关系对于开发有效的基于黄金的癌症疗法至关重要.
研究的目的:
- 为了审查结构性特征的黄金 (I) 复合物,这些复合物来自于自然灵感的连接物.
- 强调连接体结构和金色协调对生物活动的影响.
- 提供结构-活动视角,并确定未来的研究机会.
主要方法:
- 合成各种自然灵感的黄金 (I) 复合物,包括基,N-异环碳 (NHC),异原子供体和异金属类型.
- 这些黄金 (I) 复合体的结构特征.
- 分析与复杂结构相关的临床前抗癌活性数据.
主要成果:
- 受到大自然启发的金 (I) 复合物表现出有希望的临床前抗癌活性.
- 干设计和金色协调显著影响细胞毒性,稳定性和机理多样性.
- 多种复杂类型 (基尼尔,NHC等) 有助于增强治疗潜力.
结论:
- 灵感来自大自然的金复合体代表了抗癌药物发现的有希望的途径.
- 理性设计策略专注于连接体结构和协调化学可以优化抗癌疗效.
- 对这些复杂物质的进一步研究有可能发展出新的癌症治疗方法.
更多相关视频
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
14.5K
08:26Luminophore Formation in Various Conformations of Bovine Serum Albumin by Binding of GoldIII
Published on: August 31, 2018
7.3K
相关概念视频
Ligand Binding Sites
15.4K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.4K
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Metal-Ligand Bonds
24.8K
The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
24.8K
Targets for Drug Action: Overview
10.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K
